Last reviewed · How we verify

Rovi Pharmaceuticals Laboratories — Portfolio Competitive Intelligence Brief

Rovi Pharmaceuticals Laboratories pipeline: 2 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
ISM® ISM® marketed Other
Clexane Clexane marketed Other
Placebo of Risperidone ISM Placebo of Risperidone ISM phase 3 Psychiatry

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Rovi Pharmaceuticals Laboratories:

Cite this brief

Drug Landscape (2026). Rovi Pharmaceuticals Laboratories — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/rovi-pharmaceuticals-laboratories. Accessed 2026-05-17.

Related